Next Article in Journal
Viral Carcinogenesis: Factors Inducing DNA Damage and Virus Integration
Previous Article in Journal
Mutational Analysis of Merkel Cell Carcinoma
Previous Article in Special Issue
Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(4), 2137-2154; doi:10.3390/cancers6042137

Desmoplasia and Chemoresistance in Pancreatic Cancer

1
Division of Gastroenterology, Endocrinology and Metabolism, University Hospital, Philipps-Universitaet Marburg, Baldingerstrasse, Marburg 35043, Germany
2
Department of Medicine II (Department of Gastroenterology, Hepatology, and Infectious Diseases), University Medical Center Mannheim (UMM), Theodor-Kutzer-Ufer 1-3, Mannheim 68135, Germany
3
Lung Cancer, Genomics/Epigenomics Group, Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69121, Germany
4
Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, SE-141 52 Huddinge, Sweden
5
Gastrocentrum, Karolinska University Hospital, Stockholm, Stockholm 141 86, Sweden
*
Author to whom correspondence should be addressed.
Received: 29 April 2014 / Revised: 8 September 2014 / Accepted: 24 September 2014 / Published: 21 October 2014
(This article belongs to the Special Issue Cancer Drug Resistance)
View Full-Text   |   Download PDF [633 KB, uploaded 21 October 2014]   |  

Abstract

Pancreatic ductal adenocarcinoma (PDAC) occurs mainly in people older than 50 years of age. Although great strides have been taken in treating PDAC over the past decades its incidence nearly equals its mortality rate and it was quoted as the 4th leading cause of cancer deaths in the U.S. in 2012. This review aims to focus on research models and scientific developments that help to explain the extraordinary resistance of PDAC towards current therapeutic regimens. Furthermore, it highlights the main features of drug resistance including mechanisms promoted by cancer cells or cancer stem cells (CSCs), as well as stromal cells, and the acellular components surrounding the tumor cells—known as peritumoral desmoplasia—that affects intra-tumoral drug delivery. Finally, therapeutic concepts and avenues for future research are suggested, based on the topics discussed. View Full-Text
Keywords: pancreatic cancer; desmoplasia; drug resistance; SFM-DR; CAM-DR; de novo resistance; cancer stem cells; matrix; future therapies pancreatic cancer; desmoplasia; drug resistance; SFM-DR; CAM-DR; de novo resistance; cancer stem cells; matrix; future therapies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schober, M.; Jesenofsky, R.; Faissner, R.; Weidenauer, C.; Hagmann, W.; Michl, P.; Heuchel, R.L.; Haas, S.L.; Löhr, J.-M. Desmoplasia and Chemoresistance in Pancreatic Cancer. Cancers 2014, 6, 2137-2154.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top